Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

Bone Mineral Density to Assess Pediatric Bone Health in Drug Development.

Maas BM, Wang J, Cooner F, Green D, Yuan Y, Yao L, Burckart GJ.

Ther Innov Regul Sci. 2017 Nov;51(6):756-760. doi: 10.1177/2168479017709047. Epub 2017 May 11.

PMID:
30227097
2.

A Pharmacokinetic/Pharmacodynamic Model to Predict Effective HIV Prophylaxis Dosing Strategies for People Who Inject Drugs.

Garrett KL, Chen J, Maas BM, Cottrell ML, Prince HA, Sykes C, Schauer AP, White N, Dumond JB.

J Pharmacol Exp Ther. 2018 Nov;367(2):245-251. doi: 10.1124/jpet.118.251009. Epub 2018 Aug 27.

PMID:
30150483
3.
4.

Primary Endpoints in Pediatric Efficacy Trials Submitted to the US FDA.

Green DJ, Burnham JM, Schuette P, Liu XI, Maas BM, Yao L, McCune SK, Chen J, van den Anker JN, Burckart GJ.

J Clin Pharmacol. 2018 Jul;58(7):885-890. doi: 10.1002/jcph.1109. Epub 2018 Apr 17.

5.

Concentrations of Pro-Inflammatory Cytokines Are Not Associated with Senescence Marker p16INK4a or Predictive of Intracellular Emtricitabine/Tenofovir Metabolite and Endogenous Nucleotide Exposures in Adults with HIV Infection.

Maas BM, Francis O, Mollan KR, Lee C, Cottrell ML, Prince HM, Sykes C, Trezza C, Torrice C, White N, Malone S, Hudgens MG, Sharpless NE, Dumond JB.

PLoS One. 2016 Dec 30;11(12):e0168709. doi: 10.1371/journal.pone.0168709. eCollection 2016.

Supplemental Content

Support Center